Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pf-04531083. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A known ✓ | Q9Y5Y9 | 13/20 | 1.00 |
| ▸ | SCN9A | Q15858 | 2/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-04531083 SCHEMBL29387055 | 1.00 | SCN10A (1.00) | SCN10ASCN9ASCN1ASCN5AHTT | |
| SCHEMBL14237647 | 0.90 | SCN10A (0.81) | SCN10ASCN9ASCN1ASCN5AHTT | |
| SCHEMBL14237441 | 0.90 | SCN10A (0.81) | SCN10ASCN9ASCN1ASCN5AHTT | |
| SCHEMBL264604 | 0.89 | SCN10A (0.81) | SCN10ASCN9ASCN1ASCN5AHTT | |
| SCHEMBL14237498 | 0.89 | SCN10A (0.80) | SCN10ASCN9ASCN1ASCN5AHTT | |
| SCHEMBL263773 | 0.89 | SCN10A (0.79) | SCN10ASCN9ASCN1ASCN5AHTT | |
| SCHEMBL261800 | 0.88 | SCN10A (1.00) | SCN10ASCN9ASCN1ASCN5AHTT | |
| SCHEMBL263924 | 0.88 | SCN10A (0.78) | SCN10ASCN9ASCN1ASCN5AHTT | |
| SCHEMBL14237512 | 0.87 | SCN10A (0.83) | SCN10ASCN9ASCN1ASCN5AHTT | |
| SCHEMBL14237524 | 0.86 | SCN10A (0.76) | SCN10ASCN9ASCN1ASCN5ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183241-B1 | 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LTD (GB) | 2012-12-19 | — | — | EP | claimed |
| US-8134007-B2 | Pyridine derivatives | PFIZER INC. (US) | 2012-03-13 | — | — | US | claimed |
| JP-4657384-B2 | — | — | 2011-03-23 | — | — | JP | claimed |
| JP-2010526050-A | — | — | 2010-07-29 | — | — | JP | claimed |
| EP-2183241-A2 | 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | Pfizer Limited (GB) | 2010-05-12 | — | — | EP | claimed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | claimed |
| WO-2008135826-A2 | 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LIMITED (GB) | 2008-11-13 | — | — | WO | claimed |
| EP-4714435-A2 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | Vertex Pharmaceuticals Incorporated (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4699607-A2 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-01 | — | — | US | disclosed |
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| US-20110207654-A1 | PEPTIDE ANALOGUES | PFIZER INC. | 2011-08-25 | — | — | US | disclosed |
| WO-2011077313-A1 | PIPERIDINECARBOXAMIDES AS MPGES - 1 INHIBITORS | PFIZER INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | SCN10A 37/4885SCN9A 73/4885SCN1A 23/4885 |
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN8A, SCN1B, SCN3A | SCN10A 22/4885SCN9A 18/4885SCN1A 6/4885 |
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN1B, CLIC1, HCN1 | SCN10A 37/4885SCN9A 43/4885SCN1A 4/4885 |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | CNR1, SCN1B, OPRL1 | SCN10A 94/4885SCN9A 96/4885SCN1A 23/4885 |
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN1A, SCN1B | SCN10A 10/4885SCN9A 9/4885SCN1A 2/4885 |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | SDHA, P2RX4, P2RX3 | SCN10A 358/4885SCN9A 491/4885SCN1A 224/4885 |
| US-20110207654-A1 | PEPTIDE ANALOGUES | OPRL1, OGFR, OPRM1 | SCN10A 434/4885SCN9A 673/4885SCN1A 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.